Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, De Falco V, Upadhyay A, Kandimalla R, Chaudhary A, Dhanjal JK, Dewanjee S, Vallamkondu J, de la Pérez JM (2023) Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. In Genes and Diseases (Vol. 10, Issue 4). https://doi.org/10.1016/j.gendis.2022.02.007

Anciones C, Gil-Nagel A (2020) Adverse effects of cannabinoids. Epileptic Disord 22(1). https://doi.org/10.1684/epd.2019.1125

Anderson PF, Jackson DM, Chesher GB, Malor R (1975) Tolerance to the effects of ∆9-tetrahydrocannabinol in mice on intestinal motility, temperature and locomotor activity. Psychopharmacologia 43(1). https://doi.org/10.1007/BF00437611

Bacalhau C, Costa-Pereira JT, Tavares I (2023) Preclinical research in paclitaxel-induced neuropathic pain: a systematic review. In Frontiers in Veterinary Science (Vol. 10). https://doi.org/10.3389/fvets.2023.1264668

Bachmanov AA, Reed DR, Beauchamp GK, Tordoff MG (2002) Food intake, water intake, and drinking spout side preference of 28 mouse strains. Behav Genet 32(6). https://doi.org/10.1023/A:1020884312053

Bahji A, Meyyappan AC, Hawken ER (2020) Efficacy and acceptability of cannabinoids for anxiety disorders in adults: A systematic review & meta-analysis. J Psychiatr Res 129. https://doi.org/10.1016/j.jpsychires.2020.07.030

Berthold EC, Kamble SH, Kanumuri SRR, Kuntz MA, Senetra AS, Chiang YH, McMahon LR, McCurdy CR, Sharma A (2023) Comparative pharmacokinetics of commercially available Cannabidiol isolate, Broad-Spectrum, and Full-Spectrum products. Eur J Drug Metab Pharmacokinet 48(4). https://doi.org/10.1007/s13318-023-00839-3

Blanton HL, Brelsfoard J, DeTurk N, Pruitt K, Narasimhan M, Morgan DJ, Guindon J (2019) Cannabinoids: current and future options to treat chronic and Chemotherapy-Induced neuropathic pain. Drugs 79(9):969–995. https://doi.org/10.1007/s40265-019-01132-x

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bruijnzeel AW, Qi X, Guzhva LV, Wall S, Deng JV, Gold MS, Febo M, Setlow B (2016) Behavioral characterization of the effects of cannabis smoke and Anandamide in rats. PLoS ONE 11(4). https://doi.org/10.1371/journal.pone.0153327

Burgess J, Matsumoto ÁK, Marshall ÁA, Alam ÁU, Ferdousi M, Gosal D, Mak T, Boon C, Marshall A, Frank ÁB, Malik RA, Alam U (2021) Chemotherapy-Induced peripheral neuropathy: epidemiology, pathomechanisms and treatment. Oncol Then 9:385–450. https://doi.org/10.1007/s40487-021-00168-y

Article  Google Scholar 

Calapai F, Cardia L, Calapai G, Di Mauro D, Trimarchi F, Ammendolia I, Mannucci C (2022) Effects of Cannabidiol on Locomotor Activity. In Life (Vol. 12, Issue 5). https://doi.org/10.3390/life12050652

Campos RMP, Aguiar AFL, Paes-Colli Y, Trindade PMP, Ferreira BK, de Melo Reis RA, Sampaio LS (2021) Cannabinoid Therapeutics in Chronic Neuropathic Pain: From Animal Research to Human Treatment. In Frontiers in Physiology (Vol. 12). https://doi.org/10.3389/fphys.2021.785176

Casadei M, Fiore E, Rubione J, Domínguez LM, Coronel MF, Leiguarda C, García M, Mazzolini G, Villar MJ, Montaner A, Constandil L, Romero-Sandoval A, Brumovsky PR (2021) IMT504 blocks allodynia in rats with spared nerve injury by promoting the migration of mesenchymal stem cells and by favoring an anti-inflammatory milieu at the injured nerve. Pain 163(6):1114–1129. https://doi.org/10.1097/j.pain.0000000000002476

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cavaletti G, Marmiroli P, Renn CL, Dorsey SG, Serra MP, Quartu M, Meregalli C (2021) Cannabinoids: an effective treatment for Chemotherapy-Induced peripheral neurotoxicity?? Neurotherapeutics: J Am Soc Experimental Neurother 18(4):2324–2336. https://doi.org/10.1007/S13311-021-01127-1

Article  CAS  Google Scholar 

Chaplan SR, Bach F, Pogrel J, Chung J, Yaksh TL (1994) Quantitaive assesment of tactil allodynia in the Raw paw. J Neurosci Methods 1:55–63. https://doi.org/10.1016/0165-0270(94)90144-9

Article  Google Scholar 

Choi Y, Yoon YW, Na HS, Kim SH, Chung JM (1994) Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain. Pain, 59(3)

Cimbro E, Dessì M, Ziranu P, Madeddu C, Atzori F, Lai E, Pretta A, Mariani S, Donisi C, Spanu D, Pozzari M, Murgia S, Saba G, Codipietro C, Palmas E, Sanna G, Semonella F, Sardo S, Finco G, Scartozzi M (2024) Early taxane exposure and neurotoxicity in breast cancer patients. Supportive Care Cancer: Official J Multinational Association Supportive Care Cancer 32(10):709. https://doi.org/10.1007/s00520-024-08908-2

Article  Google Scholar 

Comelli F, Giagnoni G, Bettoni I, Colleoni M, Costa B (2008) Antihyperalgesic effect of a cannabis sativa extract in a rat model of neuropathic pain: mechanisms involved. Phytother Res 22(8). https://doi.org/10.1002/ptr.2401

Costa B, Colleoni M, Conti S, Parolaro D, Franke C, Trovato AE, Giagnoni G (2004) Oral anti-inflammatory activity of Cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn-Schmiedeberg’s Archives Pharmacol 369(3). https://doi.org/10.1007/s00210-004-0871-3

D’Andre S, McAllister S, Nagi J, Giridhar KV, Ruiz-Macias E, Loprinzi C (2021) Topical cannabinoids for treating Chemotherapy-Induced neuropathy: A case series. Integr Cancer Ther 20. https://doi.org/10.1177/15347354211061739

da Costa R, Passos GF, Quintão NLM, Fernandes ES, Maia JRLCB, Campos MM, Calixto JB (2020) Taxane-induced neurotoxicity: pathophysiology and therapeutic perspectives. Br J Pharmacol 177(14):3127–3146. https://doi.org/10.1111/BPH.15086

Article  PubMed  PubMed Central  Google Scholar 

Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloux F, Wong M, Tilton N, Bruno P, Bluvstein J, Hedlund J, Kamens R, Maclean J, Nangia S, Singhal NS, Cilio MR (2016) Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 15(3). https://doi.org/10.1016/S1474-4422(15)00379-8

Dixon W (1980) Efficient analysis of experimental observation. Pharmacologia Annual Rev Pharmacol Toxicol 20:441–462. https://doi.org/10.1146/annurev.pa.20.040180.002301

Article  CAS  Google Scholar 

Doğan B, Gökhan U (2024) Hepatotoxicity of Anti-cancer drugs. Interdisciplinary cancer research. Springer, Cham

Google Scholar 

dos Santos RG, Hallak JEC, Crippa JAS (2021) Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review. In Advances in Experimental Medicine and Biology (Vol. 1264). https://doi.org/10.1007/978-3-030-57369-0_3

Duncan RS, Riordan SM, Gernon MC, Koulen P (2024) Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: Preclinical models and clinical studies. In Neural Regeneration Research (Vol. 19, Issue 4). https://doi.org/10.4103/1673-5374.382220

Dupire A, Kant P, Mons N, Marchand AR, Coutureau E, Dalrymple-Alford J, Wolff M (2013) A role for anterior thalamic nuclei in affective cognition: interaction with environmental conditions. Hippocampus 23(5):392–404. https://doi.org/10.1002/HIPO.22098

Article  PubMed  CAS  Google Scholar 

Espejo-Porras F, Fernández-Ruiz J, Pertwee RG, Mechoulam R, García C (2013) Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. Neuropharmacology 75:155–163. https://doi.org/10.1016/j.neuropharm.2013.07.024

Freeman AM, Petrilli K, Lees R, Hindocha C, Mokrysz C, Curran HV, Saunders R, Freeman TP (2019) How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. In Neuroscience and Biobehavioral Reviews (Vol. 107). https://doi.org/10.1016/j.neubiorev.2019.09.036

García-Arencibia M, González S, de Lago E, Ramos JA, Mechoulam R, Fernández-Ruiz J (2007) Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res 1134(1). https://doi.org/10.1016/j.brainres.2006.11.063

Guimarães FS, Chiaretti TM, Graeff FG, Zuardi AW (1990) Antianxiety effect of Cannabidiol in the elevated plus-maze. Psychopharmacology 100(4). https://doi.org/10.1007/BF02244012

Gurgenci T, Hardy J, Huggett G, Foster K, Pelecanos A, Greer R, Philip J, Haywood A, Mendis R, Yates P, Good P (2024) Medicinal cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer-a study protocol for a randomised controlled trial. Trials 25(1). https://doi.org/10.1186/S13063-024-08091-Z

Hansen JS, Gustavsen S, Roshanisefat H, Kant M, Biering-Sørensen F, Andersen C, Olsson A, Chow HH, Asgari N, Hansen JR, Nielsen HH, Hansen RM, Petersen T, Oturai AB, Sellebjerg F, Sædder EA, Kasch H, Rasmussen PV, Finnerup NB, Svendsen KB (2023) Cannabis-Based medicine for neuropathic pain and Spasticity—A multicenter, randomized, Double-Blinded, Placebo-Controlled trial. Pharmaceuticals 16(8). https://doi.org/10.3390/ph16081079

Hardy JR, Greer R, Gurgenci T, Kearney A, Ladwa R, Huggett G, Good P (2024) A randomized, double-blind controlled trial of medicinal cannabis vs placebo for symptom management in patients with advanced cancer receiving palliative care. J Clin Oncol 42(16suppl):12020–12020. https://doi.org/10.1200/JCO.2024.42.16_SUPPL.12020

Article  Google Scholar 

Harris HM, Sufka KJ, Gul W, Elsohly MA (2016) Effects of Delta-9-Tetrahydrocannabinol and Cannabidiol on Cisplatin-Induced neuropathy in mice. Planta Med 82(13). https://doi.org/10.1055/s-0042-106303

Hasbi A, Madras BK, George SR (2023) Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review. In Brain Sciences (Vol. 13, Issue 2). https://doi.org/10.3390/brainsci13020325

Henson JD, Vitetta L, Hall S (2022) Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions. In Inflammopharmacology (Vol. 30, Issue 4). https://doi.org/10.1007/s10787-022-01020-z

Hess LM, Barakat R, Tian C, Ozols RF, Alberts DS (2007) Weight change during chemotherapy as a potential prognostic factor for stage Iii epithelial ovarian carcinoma: A gynecologic oncology group study. Gynecol Oncol 107(2):260. https://doi.org/10.1016/J.YGYNO.2007.06.010

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hložek T, Uttl L, Kadeřábek L, Balíková M, Lhotková E, Horsley RR, Nováková P, Šíchová K, Štefková K, Tylš F, Kuchař M, Páleníček T (2017) Pharmacokinetic and behavioural profile of THC, CBD, and THC + CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC. Eur Neuropsychopharmacol 27(12):1223–1237. https://doi.org/10.1016/j.euroneuro.2017.10.037

Article  PubMed  CAS  Google Scholar 

Ibrahim EY, Ehrlich BE (2020) Prevention of Chemotherapy-Induced peripheral neuropathy: A review of recent findings. Crit Rev Oncol Hematol 145. https://doi.org/10.1016/j.critrevonc.2019.102831

Inglet S, Winter B, Yost SE, Entringer S, Lian A, Biksacky M, Pitt RD, Mortensen W (2020) Clinical Data for the Use of Cannabis-Based Treatments: A Comprehensive Review of the Literature. In Annals of Pharmacotherapy (Vol. 54, Issue 11). https://doi.org/10.1177/1060028020930189

Järbe TUC, DiPatrizio NV (2005) ∆9-THC induced hyperphagia and tolerance assessment: interactions between the CB1 receptor agonist ∆9-THC and the CB1 receptor antagonist SR-141716 (rimonabant) in rats. Behav Pharmacol 16:5–6. https://doi.org/10.1097/00008877-200509000-00009

Article  Google Scholar 

Järbe TUC, Andrzejewski ME, DiPatrizio NV (2002) Interactions between the CB1 receptor agonist ∆9-THC and the CB1 receptor antagonist SR-141716 in rats: Open-field revisited. Pharmacol Biochem Behav 73(4). https://doi.org/10.1016/S0091-3057(02)00938-3

Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT (2010) Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manag 39(2):167–179. https://doi.org/10.1016/J.JPAINSYMMAN.2009.06.008

Article  Google Scholar 

Jurga M, Jurga A, Jurga K, Kaźmierczak B, Kuśmierczyk K, Chabowski M (2024) Cannabis-Based Phytocannabinoids: Overview, Mechanism of Action, Therapeutic Application, Production, and Affecting Environmental Factors. In International Journal of Molecular Sciences (Vol. 25, Issue 20). Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/ijms252011258

Kaizu M, Komatsu H, Yamauchi H, Yamauchi T, Sumitani M, Doorenbos AZ (2021) Characteristics of taste alterations in people receiving taxane-based chemotherapy and their association with appetite, weight, and quality of life. Support Care Cancer 29(9). https://doi.org/10.1007/s00520-021-06066-3

Karniol IG, Carlini EA (1973) Pharmacological interaction between Cannabidiol and δ9-tetrahydrocannabinol. Psychopharmacologia 33(1). https://doi.org/10.1007/BF00428793

King KM, Myers AM, Soroka-Monzo AJ, Tuma RF, Tallarida RJ, Walker EA, Ward SJ (2017) Single and combined effects of ∆9-tetrahydrocannabinol and Cannabidiol in a mouse model of chemotherapy-induced neuropathic pain. Br J Pharmacol 174(17):2832–2841. https://doi.org/10.1111/bph.13887

Article  PubMed  PubMed Central  CAS  Google Scholar 

Klein C, Karanges E, Spiro A, Wong A, Spencer J, Huynh T, Gunasekaran N, Karl T, Long LE, Huang XF, Liu K, Arnold JC, McGregor IS (2011) Cannabidiol potentiates ∆ 9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology 218(2). https://doi.org/10.1007/s00213-011-2342-0

Kurt B, Karslı ZS, Öksüzoğlu BÖÇ, Öztürk E, Demirörs N, Dağ O (2023) Determination of the influence of peripheral neuropathy symptoms on quality of life in breast cancer patients: A Cross-Sectional study with four Follow-Ups. Florence Nightingale J Nurs 31(2). https://doi.org/10.5152/FNJN.2023.22156

Laaksonen KS, Nevalainen TO, Haasio K, Kasanen IHE, Nieminen PA, Voipio HM (2013) Food and water intake, growth, and adiposity of Sprague-Dawley rats with diet board for 24 months. Lab Anim 47(4). https://doi.org/10.1177/0023677213488103

Langford RM, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, Ratcliffe S (2013) A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol 260(4):984–997. https://doi.org/10.1007/S00415-012-6739-4

Article  PubMed  CAS  Google Scholar 

Lever C, Burton S, O’Keefe J (2006) Rearing on hind legs, environmental novelty, and the hippocampal formation. In Reviews in the Neurosciences (Vol. 17, Issues 1–2). https://doi.org/10.1515/REVNEURO.2006.17.1-2.111

Lichtman AH, Martin BR (1991) Spinal and supraspinal components of cannabinoid-induced antinociception. J Pharmacol Exp Ther, 258(2)

Ligresti A, De Petrocellis L, Di Marzo V (2016) From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex Pharmacology. Physiol Rev 96(4). https://doi.org/10.1152/physrev.00002.2016

Liu S, Ni J, Yan F, Yin N, Li X, Ma R, Wu J, Zhou G, Feng J (2022) Functional changes of the prefrontal cortex, insula, caudate and associated cognitive impairment (chemobrain) in NSCLC patients receiving different chemotherapy regimen. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.1027515

Long LE, Chesworth R, Huang XF, McGregor IS, Arnold JC, Karl T (2010) A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and Cannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol 13(7):861–876. https://doi.org/10.1017/S1461145709990605

Article  PubMed